Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 2Terminated 1Recruiting 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 35Sarcoma 2Dermatologic 2Tumor-Agnostic 1Thoracic 1Other solid neoplasm 1NET 1Head & Neck 1Genitourinary 1Endocrine 1Breast 1

Conditions

Melanoma 2

Interventions

Nivolumab 27pembrolizumab 22Ipilimumab 17Temozolomide 13toripalimab 12Biopsy 10Cyclophosphamide 9Imiquimod 8Dacarbazine 7Blood Specimen Collection 7camrelizumab 6Chemotherapy, Adjuvant 6trametinib 5fludarabine 5dabrafenib 5atezolizumab 5aldesleukin 5Gene Expression Profiling 5Cisplatin 5Aminolevulinic Acid 5fludarabine phosphate 4durvalumab 4binimetinib 4apatinib 4Tomography, Optical Coherence 4Sorafenib 4Photochemotherapy 4Interleukin-2 4Injections 4Carboplatin 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unknown × regorafenib × Dermatologic × Clear all
NCT05370807 2023-10-24

RegoMel

Universitair Ziekenhuis Brussel

Phase 2 Unknown
48 enrolled
Dermatologic

Melanoma

NCT02501551 2021-04-05

Regorafenib, C-kit Mutated Malignant Melanoma, 2nd Line Therapy

Yonsei University

Phase 2 Unknown
36 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡